These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34167853)

  • 21. Protection of mice against brucellosis by intranasal immunization with Brucella melitensis lipopolysaccharide as a noncovalent complex with Neisseria meningitidis group B outer membrane protein.
    Bhattacharjee AK; Van de Verg L; Izadjoo MJ; Yuan L; Hadfield TL; Zollinger WD; Hoover DL
    Infect Immun; 2002 Jul; 70(7):3324-9. PubMed ID: 12065469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral immunization of mice with Omp31-loaded
    Abkar M; Fasihi-Ramandi M; Kooshki H; Sahebghadam Lotfi A
    Int J Nanomedicine; 2017; 12():8769-8778. PubMed ID: 29263667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge.
    Kahl-McDonagh MM; Arenas-Gamboa AM; Ficht TA
    Infect Immun; 2007 Oct; 75(10):4923-32. PubMed ID: 17664263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.
    Abkar M; Lotfi AS; Amani J; Eskandari K; Ramandi MF; Salimian J; Brujeni GN; Alamian S; Kamali M; Koushki H
    Vet Res Commun; 2015 Dec; 39(4):217-28. PubMed ID: 26395469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from Brucella melitensis.
    Al-Mariri A; Abbady AQ
    J Infect Dev Ctries; 2013 Apr; 7(4):329-37. PubMed ID: 23592643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
    Singh D; Somani VK; Aggarwal S; Bhatnagar R
    Mol Immunol; 2015 Dec; 68(2 Pt A):272-9. PubMed ID: 26442664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between immune responses and resistance induced in BALB/c mice vaccinated with RB51 and Rev. 1 vaccines and challenged with Brucella melitensis bv. 3.
    Hamdy ME; El-Gibaly SM; Montasser AM
    Vet Microbiol; 2002 Aug; 88(1):85-94. PubMed ID: 12119140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD8 knockout mice are protected from challenge by vaccination with WR201, a live attenuated mutant of Brucella melitensis.
    Yingst SL; Izadjoo M; Hoover DL
    Clin Dev Immunol; 2013; 2013():686919. PubMed ID: 24288554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a new immunogenic candidate conferring protection against Brucella melitensis infection in mice.
    Ghasemi A; Zarnani AH; Ghoodjani A; Rezania S; Salari MH; Jeddi-Tehrani M
    Mol Immunol; 2014 Nov; 62(1):142-9. PubMed ID: 24995396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein.
    Al-Mariri A
    Vaccine; 2010 Feb; 28(7):1766-70. PubMed ID: 20036752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M.
    Izadjoo MJ; Bhattacharjee AK; Paranavitana CM; Hadfield TL; Hoover DL
    Infect Immun; 2004 Jul; 72(7):4031-9. PubMed ID: 15213148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous expression of homologous and heterologous antigens in rough, attenuated Brucella melitensis.
    Bandara AB; Poff-Reichow SA; Nikolich M; Hoover DL; Sriranganathan N; Schurig GG; Dobrean V; Boyle SM
    Microbes Infect; 2009 Mar; 11(3):424-8. PubMed ID: 19397881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.
    Jain-Gupta N; Contreras-Rodriguez A; Vemulapalli R; Witonsky SG; Boyle SM; Sriranganathan N
    FEMS Immunol Med Microbiol; 2012 Dec; 66(3):436-44. PubMed ID: 23163875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved immunogenicity and protective efficacy of a divalent DNA vaccine encoding Brucella L7/L12-truncated Omp31 fusion protein by a DNA priming and protein boosting regimen.
    Golshani M; Rafati S; Siadat SD; Nejati-Moheimani M; Shahcheraghi F; Arsang A; Bouzari S
    Mol Immunol; 2015 Aug; 66(2):384-91. PubMed ID: 25968974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and evaluation of in murine model, of an improved live-vaccine candidate against brucellosis from to Brucella melitensis vjbR deletion mutant.
    Li Z; Wang S; Zhang H; Xi L; Zhang J; Zhang X; Zhou Q; Yi J; Li M; Zhang W; Zhang J
    Microb Pathog; 2018 Nov; 124():250-257. PubMed ID: 30149131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.
    Cloeckaert A; Jacques I; Grilló MJ; Marín CM; Grayon M; Blasco JM; Verger JM
    Vaccine; 2004 Jul; 22(21-22):2827-35. PubMed ID: 15246618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis.
    Gupta VK; Radhakrishnan G; Harms J; Splitter G
    Vaccine; 2012 Jun; 30(27):4017-22. PubMed ID: 22546330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice.
    Zhang J; Guo F; Chen C; Li Z; Zhang H; Wang Y; Zhang K; Du G; Li Y; Wang J; Jian T; Wang Z
    Microbiol Immunol; 2013 Jul; 57(7):502-10. PubMed ID: 23647412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of immune responses in mice and sheep inoculated with a live attenuated Brucella melitensis REV1 vaccine produced in bioreactor.
    Curina G; Nardini R; Corneli S; D'Avino N; Tentellini M; Montagnoli C; Severi G; Forti K; Paternesi B; Coletti M; Cagiola M
    Vet Immunol Immunopathol; 2018 Apr; 198():44-53. PubMed ID: 29571517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Brucella melitensis Rev.1 ΔOmp19 mutants with DIVA feature and comparison of their efficacy against three commercial vaccines in a mouse model.
    Uslu A; Erganis O
    Mol Immunol; 2021 May; 133():44-52. PubMed ID: 33631554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.